Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development

Bibliography

• PERTWEE RG: Cannabinoid receptor ligands: clinical and neuropharmacological considerations relevant to future drug discovery and development. (Invited editorial). Exp. Opin. Invest. Drugs (1996) 5:1245–1253.
   Google Scholar
• PERTWEE RG: Pharmacology of cannabinoid CBI and CB2 receptors. Pharmacol. Ther. (1997) 74:129–180.
   PubMed Web of Science ®Google Scholar
• ••A detailed review of the pharmacology of cannabinoid CBIand CB2 receptors.
   Google Scholar
• DI MARZO V, MELCK D, BISOGNO T, DE PETROCELLIS L: Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. (1998) 21:521–528.
   PubMed Web of Science ®Google Scholar
• ••A detailed review of current knowledge aboutendocannabinoids.
   Google Scholar
• RINALDI-CARMONA M, BARTH F, MILLAN J et al: SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol Exp. Ther. (1998) 284:644–650.
   PubMed Web of Science ®Google Scholar
• •First full report of the development of a potent and selective CB2 receptor antagonist/inverse agonist (SR144528).
   Google Scholar
• RINALDI-CARMONA M, BARTH F, HÉAULME M et al: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240–244.
   PubMed Web of Science ®Google Scholar
• •First full report of the development of a potent and selective CBI receptor antagonist/inverse agonist (SR141716A).
   Google Scholar
• HILLARD CJ, MANNA S, GREENBERG MJ et al.: Synthesis and characterisation of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. (1999) 289:1427–1433.
   PubMed Web of Science ®Google Scholar
• •A description of the most CB1-selective agonists yet to be developed.
   Google Scholar
• FELDER CC, JOYCE KE, BRILEY EM et al: Comparison of the pharmacology and signal transduction of the human cannabinoid CBI and CB2 receptors. Mol. Pharmacol. (1995) 48:443–450.
   PubMed Web of Science ®Google Scholar
• FELDER CC, JOYCE KE, BRILEY EM et al: LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. (1998) 284:291–297.
   PubMed Web of Science ®Google Scholar
• SHOWALTER VM, COMPTON DR, MARTIN BR, ABOOD ME Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol Exp. Ther. (1996) 278:989–999.
   PubMed Web of Science ®Google Scholar
• UN S, KHANOLKAR AD, FAN P et al.: Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J. Med. Chem. (1998) 41:5353–5361.
   PubMed Web of Science ®Google Scholar
• KHANOLKAR AD, ABADJI V, LIN S et al: Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem. (1996) 39:4515–4519.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identifi-cation of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50:83–90.
   PubMed Web of Science ®Google Scholar
• •Discovery of the endocannabinoid, 2-arachidonyl glycerol.
   Google Scholar
• RHEE M-H, VOGEL Z, BARG J et al.: Cannabinol deriva-tives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J. Med. Chem. (1997) 40:3228–3233.
   PubMed Web of Science ®Google Scholar
• BEN-SHABAT S, FRIDE E, SHESKIN T et al.: An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. (1998) 353:23–31.
   PubMed Web of Science ®Google Scholar
• PERTWEE RG, GIBSON TM, STEVENSON LA et al.: 0-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br. J. Pharmacol. (2000) 129:1577–1584.
   PubMed Web of Science ®Google Scholar
• ••Pharmacological properties of a novel, potent, water-soluble CB1/CB2 receptor agonist.
   Google Scholar
• ROSS RA, GIBSON TM, STEVENSON LA et al.: Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-A8-tetrahydroca-nnabinol at cannabinoid receptors. Br. J. Pharmacol (1999) 128:735–743.
   PubMed Web of Science ®Google Scholar
• •The introduction of a double or triple carbon-carbon bond into the alkyl side chain of the tetrahydrocannabinol molecule can produce marked changes in cannabinoid receptor efficacy without significantly affecting affinity.
   Google Scholar
• BAYEWITCH M, RHEE M-H, AVIDOR-REISS T et al: (-)-49-tetrahydrocannabinol antagonizes the periph-eral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J. Biol. Chem. (1996) 271:9902–9905.
   PubMed Web of Science ®Google Scholar
• GAREAU Y, DUFRESNE C, GALLANT M et al.: Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg. Med. Chem. Lett. (1996) 6:189–194.
   Web of Science ®Google Scholar
• ROSS RA, BROCKIE HC, STEVENSON LA et al.: Agonist-inverse agonist characterisation at CBI and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br. J. Pharmacol (1999) 126:665–672.
   PubMed Web of Science ®Google Scholar
• •Pharmacological properties of some novel CB2-selective agonists and the pharmacology of AM630 at CBI and CB2 receptors.
   Google Scholar
• SHIRE D, CALANDRA B, RINALDI-CARMONA M et al.:Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim. Biophys. Acta (1996) 1307:132–136.
   PubMed Web of Science ®Google Scholar
• HUFFMAN JW, LIDDLE J, YU S et al.: 3-(1',1'-dimethylbuty1)-1-deoxy-48-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem. (1999) 7:2905–2914.
   PubMed Web of Science ®Google Scholar
• HANUS L, BREUER A, TCHILIBON S et al: HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Nati Acad. Sci. USA (1999) 96:14228–14233.
   PubMed Web of Science ®Google Scholar
• ••A novel CB2-selective agonist with antinociceptive andanti-inflammatory properties.
   Google Scholar
• CALIGNANO A, LA RANA G, GIUFFRIDA A, PIOMELLI D: Control of pain initiation by endogenous cannabi-noids. Nature (1998) 394:277–281.
   PubMed Web of Science ®Google Scholar
• ••Evidence for a novel 'CB2-like' receptor that can mediaterelief from inflammatory pain.
   Google Scholar
• PERTWEE RG: Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. (1999) 6:635–664.
   PubMed Web of Science ®Google Scholar
• ••A detailed review of the pharmacology of cannabinoid CBIand CB2 receptor ligands.
   Google Scholar
• PERTWEE RG: Cannabinoid receptors and pain. Prog. Neurobiol (2000) (In press).
   Google Scholar
• ••A detailed review of current knowledge about the role of theendocannabinoid system in pain perception.
   Google Scholar
• BAKER D, PRYCE G, CROXFORD JL et al.: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 404:84–87.
   PubMed Web of Science ®Google Scholar
• ••The first evidence that signs of multiple sclerosis can besuppressed by both CBI and CB2 receptors.
   Google Scholar
• BOUABOULA M, PERRACHON S, MILLIGAN L et al: A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. (1997) 272:22330–22339.
   Google Scholar
• COUTTS AA, BREWSTER N, INGRAM T, RAZDAN RK, PERTWEE RG: Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. Br. J. Pharmacol (2000) 129:645–652.
   PubMed Web of Science ®Google Scholar
• KEARN CS, GREENBERG MJ, DICAMELLI R, KURZAWA K, HILLARD CJ: Relationships between ligand affinities for the cerebellar cannabinoid receptor CBI and the induction of GDP/GTP exchange. J. Neurochem. (1999) 72:2379–2387.
   PubMed Web of Science ®Google Scholar
• PAN X, IKEDA SR, LEWIS DL: SR 141716A acts as aninverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CBI cannabinoid receptor activity. Mol. Pharmacol. (1998) 54:1064–1072.
   PubMed Web of Science ®Google Scholar
• GATLEY SJ, LAN R, VOLKOW ND et al: Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CBI receptors in vivo. J. Neurochem. (1998) 70:417–423.
   PubMed Web of Science ®Google Scholar
• ••A novel radioligand that is likely to be suitable for imagingCBI receptors in living human brain by SPECT.
   Google Scholar
• GIFFORD AN, TANG Y, GATLEY SJ et al.: Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci. Lett. (1997) 238:84–86.
   PubMed Web of Science ®Google Scholar
• PERTWEE R, GRIFFIN G, FERNANDO S et al: AM630, a competitive cannabinoid receptor antagonist. Life Sci. (1995) 56:1949–1955.
   PubMed Web of Science ®Google Scholar
• GRIFFIN G, WRAY EJ, RORRER WK et al.: An investigation into the structural determinants of cannabinoid receptor ligand efficacy. Br. J. Pharmacol (1999) 126:1575–1584.
   PubMed Web of Science ®Google Scholar
• •The introduction of a double or triple carbon-carbon bond into the alkyl side chain of the tetrahydrocannabinol molecule can produce marked changes in cannabinoid receptor efficacy without significantly affecting affinity.
   Google Scholar
• BUSCH-PETERSEN J, HILL WA, FAN P et al.: Unsaturated side chain 6-11-hydroxyhexahydrocannabinol analogs. J. Med. Chem. (1996) 39:3790–3796.
   PubMed Web of Science ®Google Scholar
• PAPAHATJIS DP, KOUROULI T, ABADJI V, GOUTOPOULOS A, MAKRIYANNIS A: Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted 48-tetrahydrocannabinols. J. Med. Chem. (1998) 41:1195–1200.
   PubMed Web of Science ®Google Scholar
• BURSTEIN SH: The cannabinoid acids: nonpsychoac-tive derivatives with therapeutic potential. Pharmacol Ther. (1999) 82:87–96.
   PubMed Web of Science ®Google Scholar
• •Current knowledge about the pharmacology of the putative anti-inflammatory agent, 1',1'-dimethylheptyl-,A8-THC-11--oic acid.
   Google Scholar
• ZURIER RB, ROSSETTI RG, LANE JH et al.: Dimethylheptyl-THC-11 oic acid. A nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis and Rheumatism (1998) 41:163–170.
   Google Scholar
• •Evidence that the putative anti-inflammatory agent, 1',1'-dimethylheptyl-,A8-THC-11-oic acid, is a selective COX-2 inhibitor.
   Google Scholar
• BURSTEIN SH, FRIDERICHS E, KOGEL B, SCHNEIDER J, SELVE N: Analgesic effects of 1',l' dimethylhep-ty1-48-THC-11-oic acid (CT3) in mice. Life Sci. (1998) 63:161–168.
   PubMed Web of Science ®Google Scholar
• LAMBERT DM, DIPAOLO FG, SONVEAUX P et al.: AnaloguesandhomologuesofN-palmitoylethanolamide, a putative endogenous CB2 cannabinoid, as potential ligands for the cannabinoid receptors. Biochim. Biophys. Acta (1999) 1440:266–274.
   Google Scholar
• FACCI L, DAL TOSO R, ROMANELLO S et al.: Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoyle-thanolamide. Proc. Natl. Acad. Sci. USA (1995) 92:3376–3380.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R, FRIDE E, DI MARZO V: Endocannabinoids. Eur. J. Pharmacol. (1998) 359:1–18.
   PubMed Web of Science ®Google Scholar
• •A detailed review of current knowledge about endocannabi-noids that includes reference to the 'entourage hypothesis'.
   Google Scholar
• BISOGNO T, MAURELLI S, MELCK D, DE PETROCELLIS, L, DI MARZO, V: Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. (1997) 272:3315–3323.
   PubMed Web of Science ®Google Scholar
• PIOMELLI D, BELTRAMO M, GLASNAPP S et al.: Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA (1999) 96:5802–5807.
   PubMed Web of Science ®Google Scholar
• ••Structural determinants for recognition and translocation bythe anandamide transporter.
   Google Scholar
• BELTRAMO M, STELLA N, CALIGNANO A et al. Functional role of high-affinity anandamide transport, as © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(7) revealed by selective inhibition. Science (1997) 277:1094–1097.
   Google Scholar
• •Effects of AM404, an inhibitor of the anandamide transporter.
   Google Scholar
• CALIGNANO A, LA RANA G, BELTRAMO M, MAKRIYANNIS A, PIOMELLI D: Potentiation of anandamide hypoten-sion by the transport inhibitor, AM404. Eur. J. Pharmacol. (1997) 337:R1–R2.
   PubMed Web of Science ®Google Scholar
• GONZALEZ S, ROMERO J, DE MIGUEL R et al.: Extrapyra-midal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sci. (1999) 65:327–336.
   Google Scholar
• CALIGNANO A, LA RANA G, MAKRIYANNIS A et al: Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur. J. Pharmacol. (1997) 340:R7–R8.
   PubMed Web of Science ®Google Scholar
• GIFFORD AN, BRUNEUS M, UN S et al: Potentiation ofthe action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmityl-sulphonyl fluoride (AM 374). Eur. J. Pharmacol. (1999) 383:9–14.
   PubMed Web of Science ®Google Scholar
• KHANOLKAR AD, MAKRIYANNIS A: Structure-activity relationships of anandamide, an endogenous cannabi-noid ligand. Life Sci. (1999) 65:607–616.
   PubMed Web of Science ®Google Scholar
• ••A review of the structure-activity relationships ofanandamide that determine its affinity for CBI receptors and its capacity to serve as a substrate for fatty acid amide hydrolase and for the anandamide transporter.
   Google Scholar
• MUTHIAN SKG, JARRAHIAN A, MANNA S et al.: Structure-activity relationships for substrates and inhibitors of the neuronal anandamide uptake carrier. International Cannabinoid Research Society 1999 Symposium on the Cannabinoids. Burlington, Vermont, USA (1999):96.
   Google Scholar
• MELCK D, BISOGNO T, DE PETROCELLIS L et al.: Unsatu-rated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem. Biophys. Res. Commun. (1999) 262:275–284.
   Google Scholar
• ••A novel mixed cannabinoid receptor-vanilloid receptoragonist that also inhibits the anandamide transporter.
   Google Scholar
• MUTHIAN S, NITHIPATIKOM K, CAMPBELL WB, HILLARDCJ: Synthesis and characterisation of a fluorescent substrate for the N-arachidonoylethanolamine (anand amide) uptake carrier. J. Pharmacol. Exp. Ther. (2000) 293:289–295.
   PubMed Web of Science ®Google Scholar
• DEUTSCH DG, UN S, HILL WAG et al: Fatty acid sulfonylfluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem. Biophys. Res. Commun. (1997) 231:217–221.
   PubMed Web of Science ®Google Scholar
• •Some potent inhibitors of anandamide metabolism.
   Google Scholar
• CERVONE K, KEENE A, UN SY, MAKRIYANNIS A, SALAMONE JD: Behavioral investigation of the interac-tions between amidase inhibitors and the cannabinoid agonist anandamide. Proc. Soc. Neurosci. (1999) 25:2077.
   Google Scholar
• EDGEMOND WS, GREENBERG MJ, MCGINLEY PJ et al:Synthesis and characterisation of diazomethylarachi-donyl ketone: an irreversible inhibitor of N-arachidonylethanolamine amidohydrolase. J. Pharmacol. Exp. Ther. (1998) 286:184–190.
   PubMed Web of Science ®Google Scholar
• BELTRAMO M, DI TOMASO E, PIOMELLI D: Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthal eny1)-211-pyran-2-one. FEBS Letts. (1997) 403:263–267.
   PubMed Web of Science ®Google Scholar
• HILLARD CJ, CAMPBELL WB: Biochemistry and pharma-cology of arachidonylethanolamide, a putative endogenous cannabinoid. J. Lipid Res. (1997) 38:2383–2398.
   PubMed Web of Science ®Google Scholar
• DI MARZO V, DEUTSCH DG: Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol. Dis. (1998) 5:386–404.
   PubMed Web of Science ®Google Scholar
• PERTWEE RG: Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors. Biochem. Soc. Transact. (1998) 26:267–272.
   PubMed Web of Science ®Google Scholar
• WAGNER JA, VARGA K, JÁRAI Z, KUNOS G: Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension (1999) 33:429–434.
   PubMed Web of Science ®Google Scholar
• •Evidence for novel receptors for anandamide.
   Google Scholar
• JÁRAI Z, WAGNER JA, VARGA K et al.: Cannabinoid- induced mesenteric vasodilation through an endothe-lial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA (1999) 96:14136–14141.
   PubMed Web of Science ®Google Scholar
• ••Evidence for novel receptors for anandamide.
   Google Scholar
• VENANCE L, PIOMELLI D, GLOWINSKI J, GIAUME C: Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature (1995) 376:590–594.
   PubMed Web of Science ®Google Scholar
• •Evidence for novel receptors for anandamide.
   Google Scholar
• ADAMS IB, COMPTON DR, MARTIN BR: Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. (1998) 284:1209–1217.
   PubMed Web of Science ®Google Scholar
• SMITH FL, FUJIMORI K, LOWE J, WELCH SP: Characterisa-tion of A9-tetrahydrocannabinol and anandamide antinociception in non-arthritic and arthritic rats. Pharmacol. Biochem. Behav. (1998) 60:183–191.
   PubMed Web of Science ®Google Scholar
• DI MARZO V, BISOGNO T, MELCK D et al.: Interactionsbetween synthetic vanilloids and the endogenous cannabinoid system. FEBS Letts. (1998) 436:449–454.
   PubMed Web of Science ®Google Scholar
• BELTRAMO M, PIOMELLI D: Anandamide transport inhibition by the vanilloid agonist olvanil. Eur. J. Pharmacol. (1999) 364:75–78.
   PubMed Web of Science ®Google Scholar
• JERMAN JC, BROUGH SJ, DAVIS JB, MIDDLEMISS DN, SMART D: The anandamide transport inhibitor AM404 is an agonist at the rat vanilloid receptor (VR1). Br. J. Pharmacol. (2000) 129:73P.
   Web of Science ®Google Scholar
• ROSS RA, BROCKIE HC, LESLIE M, PASHMI G, PERTWEERG: Interactions of anandamide analogues with rat vanilloid VRi receptors. International Cannabinoid Research Society 2000 Symposium on the Cannabinoids, Burlington, Vermont (2000) (In press).
   Google Scholar
• ZYGMUNT PM, PETERSSON J, ANDERSSON DA et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 400:452-457. Evidence that anandamide is a rat vanilloid receptor agonist.
   Google Scholar
• SMART D, GUNTHORPE MJ, JERMAN JC et al.: The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. (2000) 129:227–230.
   PubMed Web of Science ®Google Scholar
• •Evidence that anandamide is a human vanilloid receptor agonist.
   Google Scholar
• MORGAN DR: Therapeutic Uses of Cannabis. Harwood Academic Publishers, Amsterdam. (1997).
   Google Scholar
• ••Comprehensive review of the therapeutic potential ofcannabinoids.
   Google Scholar
• JOY JE, WATSON SJ, BENSON JA: Marijuana and Medicine. Assessing the Science Base. National Academy Press, Washington DC, USA (1999).
   Google Scholar
• ••Contains a recent review of the therapeutic potential ofcannabinoids.
   Google Scholar
• IVERSEN LL: The Science of Marijuana. Oxford University Press, Oxford. (2000).
   Google Scholar
• •Snapshots of the cannabinoid field that allow the reader to identify many of the key issues.
   Google Scholar
• PERTWEE RG: Prescribing cannabinoids for multiple sclerosis: current issues. CNS Drugs (1999) 11:327–334.
   Web of Science ®Google Scholar
• •Cannabinoids and multiple sclerosis: a recent review.
   Google Scholar
• PERTWEE RG: Neuropharmacology and therapeutic potential of cannabinoids. Addict. Biol. (2000) 5:37–46.
   PubMed Web of Science ®Google Scholar
• •The therapeutic potential of cannabinoids: a recent review.
   Google Scholar
• SHEN M, THAYER SA: Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol (1998) 54:459–462.
   PubMed Web of Science ®Google Scholar
• DE PETROCELLIS L, MELCK D, PALMISANO A et al.: The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. ScL USA (1998) 95:8375–8380.
   PubMed Web of Science ®Google Scholar
• ••Evidence that cannabinoids are anticancer agents.
   Google Scholar
• GALVE-ROPERH I, SANCHEZ C, CORTÉS ML et al.: Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Merl. (2000) 6:313–319.
   PubMed Web of Science ®Google Scholar
• ••Evidence that cannabinoids are anticancer agents.
   Google Scholar
• GREEN K: Marijuana smoking vs. cannabinoids for glaucoma therapy. Arch. Ophthalmol. (1 9 9 8) 116:1433-1437.
   Google Scholar
• MARTIN BR, LICHTMAN AH: Cannabinoid transmission and pain perception. Neurobiol. Dis. (1998) 5:447–461.
   PubMed Web of Science ®Google Scholar
• PERTWEE RG. Cannabinoids. In: Pain: Current Understanding, Emerging Therapies and Novel Approaches to Drug Discovery. Bountra C, Munglani R, Schmidt WK (Eds.). Marcel Dekker, Basel, Switzerland (2000) (In press).
   Google Scholar
• HEMMING M, YELLOWLEES PM: Effective treatment of Tourette's syndrome with marijuana. J. Psychophar-macol. (1993) 7:389–391.
   PubMed Web of Science ®Google Scholar
• MOLLER-VAHL KR, SCHNEIDER U, KOLBE H, EMRICH HM: Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am. J. PsychiaL (1999) 156:495.
   Web of Science ®Google Scholar
• MOLLER-VAHL KR, KOLBE H, SCHNEIDER U, EMRICH HM:Cannabis in movement disorders. Forsch. Komple-mentarmed. (1999) 6\(Suppl. 3):23–27.
   Google Scholar
• •Cannabinoids and movement disorders, including Touret-te's syndrome and L-dopa-induced dyskinesia: a recent review.
   Google Scholar
• SCHON F, HART PE, HODGSON TL et al.: Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology (1999) 53:2209–2210.
   PubMed Web of Science ®Google Scholar
• CONSROE P, MUSTY R, REIN J, TILLERY W, PERTWEE R: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. (1997) 38:44–48.
   PubMed Web of Science ®Google Scholar
• RICHTER A, LOSCHER W:55,212-2, a novelcannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur. J. Pharmacol (1994) 264:371–377.
   PubMed Web of Science ®Google Scholar
• FINNEGAN-LING D, MUSTY RE: Marinol and phantom limb pain: a case study. Proc. Int. Cannabinoid. Res. Soc. (1994):53.
   Google Scholar
• JAIN AK, RYAN JR, McMAHON FG, SMITH G: Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J. Clin. Pharmacol. (1 98 1) 21:320S–326S.
   Google Scholar
• NOYES R, BRUNK SF, AVERY DH, CANTER A: The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin. Pharmacol. Ther. (1975) 18:84–89.
   PubMed Web of Science ®Google Scholar
• NOYES R, BRUNK SF, BARAM DA, CANTER A: Analgesic effect of delta-9-tetrahydrocannabinol. J. Clin. Pharmacol. (1975) 15:139–143.
   PubMed Web of Science ®Google Scholar
• BRENNEISEN R, EGLI A, ELSOHLY MA, HENN V, SPIESS Y: The effect of orally and rectally administered 49-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int. J. Clin. Pharmacol. Ther. (1996) 34:446–452.
   PubMed Web of Science ®Google Scholar
• MARTYN CN, ILLIS LS, THOM J: Nabilone in the treatment of multiple sclerosis. Lancet (1995) 345:579.
   PubMed Web of Science ®Google Scholar
• MAURER M, HENN V, DITTRICH A, HOFMANN A: Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur. Arch. PsychiaL Clin. Neurosci. (1990) 240:1–4.
   PubMed Web of Science ®Google Scholar
• HERZBERG U, ELIAV E, BENNETT GJ, KOPIN IJ: The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Letts. (1997) 221:157–160.
   PubMed Web of Science ®Google Scholar
• MAO J, PRICE DD, LU J, KENISTON L, MAYER DJ: Two distinctive antinociceptive systems in rats with pathological pain. Neurosci. Letts. (2000) 280:13–16.
   PubMed Web of Science ®Google Scholar
• RICHARDSON JD, KILO S, HARGREAVES KM: Cannabi-noids reduce hyperalgesia and inflammation via interaction with peripheral CBI receptors. Pain (1998) 75:111–119.
   PubMed Web of Science ®Google Scholar
• RICHARDSON JD, AANONSEN L, HARGREAVES KM: Antihyperalgesic effects of spinal cannabinoids. Eur. Pharmacol. (1998) 345:145–153.
   PubMed Web of Science ®Google Scholar
• BARTH F: Cannabinoid receptor agonists and antago-nists. Expert Opin. Ther. Patents (1998) 8:301–313.
   Web of Science ®Google Scholar
• ARNONE M, MARUANI J, CHAPERON F et al.: Selective inhibition of sucrose and ethanol intake by 5R141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacol. (1997) 132:104–106.
   PubMed Web of Science ®Google Scholar
• COLOMBO G, AGABIO R, DIAZ G et al.: Appetite suppression and weight loss after the cannabinoid antagonist 5R141716. Life ScL (1998) 63:PL113-PL117.
   Google Scholar
• SIMIAND J, KEANE M, KEANE PE, SOUBRIE P: SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol. (1998) 9:179–181.
   Google Scholar
• BROTCHIE JM: Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. (1998) 13:871–876.
   PubMed Web of Science ®Google Scholar
• •Evidence that CBI receptor antagonists have therapeutic potential as suppressants of L-dopa-induced dyskinesia in patients with Parkinson's disease.
   Google Scholar
• PONCELET M, BARNOUIN M-C, BRELIÈRE J-C, LE FUR G, SOUBRIE P: Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacol. (1999) 144:144–150.
   PubMed Web of Science ®Google Scholar
• TERRANOVA J-P, STORME J-J, LAFON N et al: Improve-ment of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psycho-pharmacol. (1996) 126:165–172.
   PubMed Web of Science ®Google Scholar
• HAMPSON AJ, GRIMALDI M, AXELROD J, WINK D: Cannabidiol and 0-A9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. ScL USA (1998) 95:8268–8273.
   PubMed Web of Science ®Google Scholar
• BUCKLEY NE, McCOY KL, MEZEY E et al: Immunomodu-lation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur. J. Pharmacol. (2000) 396:141–149.
   PubMed Web of Science ®Google Scholar
• •Development of CB2 knockout mice.
   Google Scholar
• LEDENT C, VALVERDE O, COSSU G et al: Unresponsive-ness to cannabinoids and reduced addictive effects of opiates in CBI receptor knockout mice. Science (1999) 283:401–404.
   PubMed Web of Science ®Google Scholar
• ••Development of CBI knockout mice.
   Google Scholar
• ZIMMER A, ZIMMER AM, HOHMANN AG, HERKENHAM M, BONNER TI: Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. ScL USA (1999) 96:5780–5785.
   PubMed Web of Science ®Google Scholar
• ••Development of CBI knockout mice.
   Google Scholar
• HOLDCROFT A, SMITH M, JACKLIN A et al.: Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia (1997) 52:483–488.
   PubMed Web of Science ®Google Scholar
• WALKER JM, HUANG SM, STRANGMAN NM, TSOU K, SARUDO-PEA MC: Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA (1999) 96:12198–12203.
   PubMed Web of Science ®Google Scholar
• ••Evidence that inflammatory pain triggers increased releaseof anandamide in the CNS.
   Google Scholar